Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.48 USD | 0.00% | -3.31% | +0.47% |
14/05 | Wedbush Adjusts Voyager Therapeutics' PT to $8 From $10, Keeps Neutral Rating | MT |
13/05 | Transcript : Voyager Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.47% | 46Cr | |
+29.03% | 4.92TCr | |
-0.10% | 4.21TCr | |
+48.43% | 4.04TCr | |
-5.26% | 2.89TCr | |
+11.48% | 2.61TCr | |
-22.74% | 1.87TCr | |
+9.06% | 1.33TCr | |
+30.01% | 1.23TCr | |
-1.51% | 1.2TCr |
- Stock Market
- Equities
- VYGR Stock
- News Voyager Therapeutics, Inc.
- Chardan Research Adjusts Price Target on Voyager Therapeutics to $6 From $4; Neutral Rating Kept